Skip to Main Content


Skip Nav Destination


Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading


In the Spotlight

Rising Stars in Cancer Immunology

Research Articles

Insufficient infiltration of solid tumors limits CAR T-cell efficacy. The authors show nonablative, tumor-targeted radiation generates a tumor-secreted chemokine gradient that facilitates CAR T-cell chemotaxis; early and higher tumor infiltration; and superior proliferation, functional persistence, and antitumor efficacy.

Data demonstrate that combining CD40 activation, CSF1R blockade, and PD-1 inhibition can overcome immune checkpoint inhibitor resistance in melanoma. Acute treatment responses are CD40 agonist–driven and enhance the function of IL12-secreting DCs to recruit activated T cells.

The authors show the cAMP activator ibudilast normalizes the tumor vasculature and improves the therapeutic efficacy of anti–PD-1 in preclinical glioblastoma models. The data uncover a role for glioblastoma-derived endothelial cells in modulating the tumor immune microenvironment.

ANXA1 promotes cancer immune escape by transcriptionally upregulating PD-L1 in cancer cells and could be a potential target for immunotherapy. Evaluating both ANXA1 and PD-L1 could serve as a predictor for efficacy and prognosis of patients receiving immunotherapy.

The authors show BMSCs induce MM-cell secretion of CXCL10, recruiting γδ T cells to BM. Hypoxia in the BM activates a SRC-3/RORγt/IL17 axis in the γδ T cells that can be targeted to reduce immunosuppression and MM progression.

The tumor microenvironment cooperatively reprograms cholesterol metabolism in monocytes, which promotes generation of semi-mature macrophages and hepatocellular carcinoma progression. Selectively modulating cholesterol metabolism in specific cell subsets within tumors may serve as an effective strategy for cancer therapy.

Ncoa2 is identified as a critical regulator for boosting mitochondrial activity during CD8+ T-cell activation via upregulation of PGC-1α expression. The data highlight the potential of targeting Ncoa2 as a cancer therapy.

The authors show c-Myb in tumor cells induces expression of immune-related genes, resulting in immunomodulation and tumor growth inhibition. The findings provide a possible mechanistic explanation for the observed better prognosis in cancer patients with higher c-Myb expression.

Close Modal

or Create an Account

Close Modal
Close Modal